Back in late January, a British artificial intelligence (AI) venture known as BenevolentAI was employed to investigate thousands of potential drug targets against SARS-CoV-2, the virus behind COVID-19. One of those targets identified was Lilly’s baricitinib. More recently, Sweden’s Karolinska Institutet as well as Imperial College London, University of Pisa, Italy and Complejo Hospitalario Universitario de Albacete, Spain led translational research investigating the efficacy of the rheumatoid arthritis drug baricitinib. It would appear that the AI didn’t lead the investigators down the incorrect path. The findings are promising: the Janus kinase (JAK) inhibitor, approved in both the United States and the European Union for rheumatoid arthritis, blocks viral entry and reduces mortality in patients with moderate to severe COVID-19. Published in the journal Science Advances, the study merits larger investment in clinical trials.
TrialSite offers a brief breakdown of this latest information. The full study can be reviewed in Science Advances.
Artificial Intelligence-Discovered the Correlation
As it turns out, back in late January, London-based BenevolentAI was employed to r...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).